Literature DB >> 9291321

Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid.

N L Wengenack1, J R Uhl, A L St Amand, A J Tomlinson, L M Benson, S Naylor, B C Kline, F R Cockerill, F Rusnak.   

Abstract

The presence of KatG(S315T), a mutation frequently detected in clinical isolates of Mycobacterium tuberculosis, has been associated with loss of catalase-peroxidase activity and resistance to isoniazid therapy. Wild-type KatG and KatG(S315T) were expressed in a heterologous host (Escherichia coli) and purified to homogeneity, and enzymatic activity was measured. The catalase activity for KatG(S315T) was reduced 6-fold, and its peroxidase activity was decreased <2-fold, compared with the activities for wild-type KatG. Pyridine hemochrome analysis demonstrated 1.1 +/- 0.1 hemes/subunit for wild-type KatG and 0.9 +/- 0.1 hemes/subunit for KatG(S315T), indicating that the difference in enzymatic activity is not the result of incomplete heme cofactor incorporation in KatG(S315T). High-performance liquid chromatography analysis showed that wild-type KatG was more efficient than KatG(S315T) at converting isoniazid to isonicotinic acid. These results demonstrate that KatG(S315T), as expressed in E. coli, is a competent catalase-peroxidase that exhibits a reduced ability to metabolize isoniazid.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291321     DOI: 10.1086/514096

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community.

Authors:  A Van Rie ; R Warren; I Mshanga; A M Jordaan; G D van der Spuy ; M Richardson; J Simpson; R P Gie; D A Enarson; N Beyers; P D van Helden ; T C Victor
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

2.  Exploring the structure and function of the mycobacterial KatG protein using trans-dominant mutants.

Authors:  Joseph A DeVito; Sheldon Morris
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis.

Authors:  B Saint-Joanis; H Souchon; M Wilming; K Johnsson; P M Alzari; S T Cole
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

4.  Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.

Authors:  Tali H Reingewertz; Tom Meyer; Fiona McIntosh; Jaryd Sullivan; Michal Meir; Yung-Fu Chang; Marcel A Behr; Daniel Barkan
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.

Authors:  M Caws; Phan Minh Duy; Dau Quang Tho; Nguyen Thi Ngoc Lan; Dai Viet Hoa; Jeremy Farrar
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

6.  Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis.

Authors:  H Rinder; A Thomschke; S Rüsch-Gerdes; G Bretzel; K Feldmann; M Rifai; T Löscher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-07       Impact factor: 3.267

7.  Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.

Authors:  Justin L Kandler; Alexandra D Mercante; Tracy L Dalton; Matthew N Ezewudo; Lauren S Cowan; Scott P Burns; Beverly Metchock; Peter Cegielski; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities.

Authors:  Christine E Cade; Adrienne C Dlouhy; Katalin F Medzihradszky; Saida Patricia Salas-Castillo; Reza A Ghiladi
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

9.  Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo.

Authors:  Graham S Timmins; Sharon Master; Frank Rusnak; Vojo Deretic
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

10.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Authors:  Indra L Bergval; Anja R J Schuitema; Paul R Klatser; Richard M Anthony
Journal:  J Antimicrob Chemother       Date:  2009-07-04       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.